Autopsy report · NCT00387738
Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults
Cause of deathFutility
“Interim data indicated that subjects exhibited no meaningful allergic disease during the first ragweed season, making it impossible to measure treatment effect.”
Life of this trial
- Registered 6 months after it had already started.
- Ran for about 1 year 11 months before it stopped.
- 738 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Dynavax Technologies Corporation
- Sponsor type
- Industry
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate; Histamine base
- Participants
- 738
- Sites
- 28
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.